Li-Yuan Bai

3.8k total citations
42 papers, 869 citations indexed

About

Li-Yuan Bai is a scholar working on Molecular Biology, Oncology and Surgery. According to data from OpenAlex, Li-Yuan Bai has authored 42 papers receiving a total of 869 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Molecular Biology, 13 papers in Oncology and 8 papers in Surgery. Recurrent topics in Li-Yuan Bai's work include Autophagy in Disease and Therapy (6 papers), Genomics, phytochemicals, and oxidative stress (5 papers) and Bioactive Compounds and Antitumor Agents (4 papers). Li-Yuan Bai is often cited by papers focused on Autophagy in Disease and Therapy (6 papers), Genomics, phytochemicals, and oxidative stress (5 papers) and Bioactive Compounds and Antitumor Agents (4 papers). Li-Yuan Bai collaborates with scholars based in Taiwan, United States and Egypt. Li-Yuan Bai's co-authors include Chang-Fang Chiu, Jing‐Ru Weng, Shih-Jiuan Chiu, Aaron M. Sargeant, Po‐Chen Chu, Chia-Yung Wu, Ming-Hsui Tsai, Ching-Shih Chen, Su-Peng Yeh and En‐Chi Hsu and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Scientific Reports.

In The Last Decade

Li-Yuan Bai

41 papers receiving 851 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Li-Yuan Bai Taiwan 17 466 150 109 102 99 42 869
Shuming Sun China 21 566 1.2× 120 0.8× 72 0.7× 144 1.4× 145 1.5× 51 959
Xiaohong Yang China 17 610 1.3× 247 1.6× 90 0.8× 119 1.2× 183 1.8× 56 1.1k
Aintzane Asumendi Spain 22 723 1.6× 259 1.7× 112 1.0× 346 3.4× 144 1.5× 47 1.2k
Randall Evans United States 13 609 1.3× 220 1.5× 83 0.8× 117 1.1× 132 1.3× 24 991
Oleksii Dubrovskyi United States 16 477 1.0× 172 1.1× 42 0.4× 126 1.2× 95 1.0× 27 946
Paola Bargagna‐Mohan United States 17 592 1.3× 193 1.3× 35 0.3× 100 1.0× 122 1.2× 23 1.3k
Beata Olejnicka Sweden 12 325 0.7× 75 0.5× 71 0.7× 74 0.7× 133 1.3× 27 622
Kristine Misund Norway 20 669 1.4× 205 1.4× 72 0.7× 124 1.2× 146 1.5× 50 986
Yanli Jin China 23 1.1k 2.3× 289 1.9× 86 0.8× 146 1.4× 179 1.8× 45 1.5k
John G. Shelton United States 14 638 1.4× 267 1.8× 54 0.5× 85 0.8× 102 1.0× 17 929

Countries citing papers authored by Li-Yuan Bai

Since Specialization
Citations

This map shows the geographic impact of Li-Yuan Bai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Li-Yuan Bai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Li-Yuan Bai more than expected).

Fields of papers citing papers by Li-Yuan Bai

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Li-Yuan Bai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Li-Yuan Bai. The network helps show where Li-Yuan Bai may publish in the future.

Co-authorship network of co-authors of Li-Yuan Bai

This figure shows the co-authorship network connecting the top 25 collaborators of Li-Yuan Bai. A scholar is included among the top collaborators of Li-Yuan Bai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Li-Yuan Bai. Li-Yuan Bai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bai, Li-Yuan, et al.. (2025). A synthetic molecule targeting STAT3 against human oral squamous cell carcinoma cells. International Journal of Medical Sciences. 22(5). 1081–1091. 2 indexed citations
2.
3.
Chen, Chia‐Yu & Li-Yuan Bai. (2022). Long-term Remission by Nivolumab Monotherapy for Sorafenib-Refractory Hepatocellular Carcinoma. Journal of Cancer Research and Practice. 9(1). 41–44.
4.
Chiu, Chang-Fang, Jing‐Ru Weng, Chia-Yung Wu, et al.. (2020). OSU-A9 induced-reactive oxygen species cause cytotoxicity in duodenal and gastric cancer cells by decreasing phosphorylated nuclear pyruvate kinase M2 protein levels. Biochemical Pharmacology. 174. 113811–113811. 9 indexed citations
5.
Lo, Wen-Jyi, Li-Yuan Bai, Chen-Yuan Lin, et al.. (2018). Total body irradiation tremendously impair the proliferation, differentiation and chromosomal integrity of bone marrow-derived mesenchymal stromal stem cells. Annals of Hematology. 97(4). 697–707. 13 indexed citations
6.
Bai, Li-Yuan, Chang-Fang Chiu, Shih-Jiuan Chiu, Po‐Chen Chu, & Jing‐Ru Weng. (2017). FTY720 Induces Autophagy-Associated Apoptosis in Human Oral Squamous Carcinoma Cells, in Part, through a Reactive Oxygen Species/Mcl-1-Dependent Mechanism. Scientific Reports. 7(1). 5600–5600. 37 indexed citations
7.
Weng, Jing‐Ru, et al.. (2017). Cyclocommunol induces apoptosis in human oral squamous cell carcinoma partially through a Mcl-1-dependent mechanism. Phytomedicine. 39. 25–32. 7 indexed citations
8.
Bai, Li-Yuan, et al.. (2016). A triterpenoid from wild bitter gourd inhibits breast cancer cells. Scientific Reports. 6(1). 22419–22419. 49 indexed citations
9.
Chen, Hung‐Jen, Kuo‐Yang Huang, Guan-Chin Tseng, et al.. (2015). Diagnostic Pitfalls of Discriminating Lymphoma-Associated Effusions. Medicine. 94(17). e800–e800. 3 indexed citations
10.
Bai, Li-Yuan, Chang-Fang Chiu, Naval Kapuriya, et al.. (2015). BX795, a TBK1 inhibitor, exhibits antitumor activity in human oral squamous cell carcinoma through apoptosis induction and mitotic phase arrest. European Journal of Pharmacology. 769. 287–296. 39 indexed citations
11.
Bai, Li-Yuan, Jing‐Ru Weng, Chang-Fang Chiu, et al.. (2013). OSU-A9, an indole-3-carbinol derivative, induces cytotoxicity in acute myeloid leukemia through reactive oxygen species-mediated apoptosis. Biochemical Pharmacology. 86(10). 1430–1440. 25 indexed citations
12.
Bai, Li-Yuan, et al.. (2013). G15, a GPR30 antagonist, induces apoptosis and autophagy in human oral squamous carcinoma cells. Chemico-Biological Interactions. 206(2). 375–384. 48 indexed citations
13.
Lin, Po‐Han, Ching‐Chan Lin, Hwai‐I Yang, et al.. (2012). Prognostic impact of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia patients with internal tandem duplication of FLT3. Leukemia Research. 37(3). 287–292. 34 indexed citations
14.
Bai, Li-Yuan, Chang-Fang Chiu, Shiow‐Lin Pan, et al.. (2011). Antitumor activity of a novel histone deacetylase inhibitor (S)-HDAC42 in oral squamous cell carcinoma. Oral Oncology. 47(12). 1127–1133. 12 indexed citations
15.
Yeh, Su-Peng, Wen-Jyi Lo, Yu-Min Liao, et al.. (2011). Anti-leukemic therapies induce cytogenetic changes of human bone marrow-derived mesenchymal stem cells. Annals of Hematology. 91(2). 163–172. 10 indexed citations
16.
Bai, Li-Yuan, et al.. (2010). Antitumor effects of (S)-HDAC42, a phenylbutyrate-derived histone deacetylase inhibitor, in multiple myeloma cells. Cancer Chemotherapy and Pharmacology. 68(2). 489–496. 28 indexed citations
17.
Bai, Li-Yuan, et al.. (2009). OSU-03012 sensitizes TIB-196 myeloma cells to imatinib mesylate via AMP-activated protein kinase and STAT3 pathways. Leukemia Research. 34(6). 816–820. 9 indexed citations
18.
Chiou, Tzeon-Jye, et al.. (2006). Retinoblastoma in Taiwan: Survival Rate and Prognostic Factors. Japanese Journal of Ophthalmology. 50(3). 242–249. 58 indexed citations
19.
Bai, Li-Yuan, et al.. (2005). Pegylated Liposomal Doxorubicin-Based Combination Chemotherapy as Salvage Treatment in Patients With Advanced Hepatocellular Carcinoma. American Journal of Clinical Oncology. 28(6). 540–546. 6 indexed citations
20.
Bai, Li-Yuan & Shi-Chuan Chang. (2000). Disseminated Intravascular Coagulation in a Lung Cancer Patient after Acute Myocardial Infarction. The American Journal of the Medical Sciences. 320(5). 355–357. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shuming Sun Breakdown of academic impact, for papers by Xiaohong Yang Breakdown of academic impact, for papers by Aintzane Asumendi Breakdown of academic impact, for papers by Randall Evans Breakdown of academic impact, for papers by Oleksii Dubrovskyi Breakdown of academic impact, for papers by Paola Bargagna‐Mohan Breakdown of academic impact, for papers by Beata Olejnicka Breakdown of academic impact, for papers by Kristine Misund Breakdown of academic impact, for papers by Yanli Jin Breakdown of academic impact, for papers by John G. Shelton
Rankless by CCL
2026